The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD<sub>2</sub> Antibody Dinutuximab Beta

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD<sub>2</sub> Antibody Dinutuximab Beta

Treatment of high-risk neuroblastoma (NB) patients with the anti-GD<sub>2</sub> antibody (Ab) dinutuximab beta (DB) improves survival by 15%. Ab-dependent cellular cytotoxicity (ADCC) is the major mechanism of action and is primarily mediated by NK cells. Since IL-2 co-treatment did not...

Full description

Bibliographic Details
Main Authors: Nikolai Siebert, Justus Leopold, Maxi Zumpe, Sascha Troschke-Meurer, Simon Biskupski, Alexander Zikoridse, Holger N. Lode
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Cancers
Subjects:
neuroblastoma
immunotherapy
dinutuximab beta
fibroblast activation protein α
FAP-IL-2v
myeloid-derived suppressor cells
Online Access:https://www.mdpi.com/2072-6694/14/19/4842

Internet

https://www.mdpi.com/2072-6694/14/19/4842

Similar Items